| BUY | 48.390 | Alex Ruus | Pharmaceutical sector is trading at very low valuations. Good growth profile and good portfolio of drugs. Also don’t have the problem of patent expirations that Pfizer does. | 2006-11-22 | |
| BUY | 47.470 | Norman Levine | All the major drug stocks are starting to act better. In this type of market, money moves from risky stocks to defensive stocks. A good place to be. | 2006-07-25 | |
| DON'T BUY | 46.280 | Danny Tomka | All the big pharma companies are taking out a lot of costs. The problem is the pipeline is pretty lean, visability is lean. Maybe a little bit of a short term trade up to reward them for the reduced cost structure. Not significant. | 2005-07-20 | |
| TOP PICK | 36.130 | Brian Rogers | Have great new pharmaceutical products they will bring into the market in the 2006/2012 timeframe. 14 X earnings and 2 1/2 percent yield. High quality. | 2004-06-04 | |
Experts that have talked about Wyeth
Rss Top Picks Feed
